50 years since the first use of Anti-D immunoglobulin

In The News: Kamada / Jul. 1, 2018

Since 1967, the lives of countless babies have been saved by the pioneering Rh Program - and to date, millions of doses of anti-D have been given to Rh negative women.

Glassia (more than) half full: "Bioworld Today" features Kamada as its top-story

In The News: Bioworld Today / Mar. 20, 2017

This week's top- story is about Kamada's GVHD clinical program and other interesting clinical implications of its AAT pipeline.

A global leader in life-saving biopharmaceuticals: an interview with Amir London, CEO of Kamada

In The News / Dec. 26, 2016

Amir London, our CEO, explains in a special interview how Kamada saves lives and treats rare diseases with unique protein therapeutics.

Interview of CEO David Tsur on Bloomberg TV: Kamada remains focused on lung treatment

In The News: Bloomberg / Oct. 23, 2014

(Bloomberg) -- David Tsur, chief executive officer at Kamada, talks with Elliott Gotkine about what comes next for the company. He speaks on “The Pulse".

Kamada Announces Significantly Improved Infusion Rate for Glassia®

In The News: Market Watch / Apr. 24, 2014

The improved infusion rate is highly important because it reduces the overall time from preparation to finish, which is key for AATD patients who are using this therapy chronically and for life. 

Kamada starts proof-of-concept (POC) study of Glassia to treat GVHD

In The News: Pharmaceutical Business Review / Apr. 4, 2014

The POC study is a Phase I/II trial of 24 patients with steroid-resistant GVHD following allogeneic bone-marrow stem cell transplant who will receive six to ten doses of intravenously delivered Glassia to determine safety, optimal dose and clinical response.

Kamada Reports 2013 Fourth Quarter and Full Year Financial Results

In The News: The Wall Street Transcript / Feb. 5, 2014

Total revenue for the fourth quarter of 2013 increased 13% to $24.4 million from $21.6 million for the fourth quarter of 2012, reflecting higher revenue in the Proprietary Products Segment.  Total revenue increased 40% compared with the third quarter of 2013.

Kamada Announces Completion of Pivotal Phase II/III Clinical Trial in Europe and Canada of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency

In The News: Wall Street Journal / Dec. 12, 2013

The multicenter randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of Kamada's inhaled formulation of human AAT to treat AATD in >160 patients. 

Kamada expects to report top-line results from this study in the first quarter of 2014.

NASDAQ Welcomes Kamada Ltd. to The NASDAQ Stock Market

In The News: NASDAQ / May. 31, 2013

The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced that trading of Kamada Ltd. (Nasdaq:KMDA), a plasma-derived protein therapeutics company, commenced on The NASDAQ Stock Market on Friday, May 31, 2013.

out of 22 items.